HR27-119

What This Bill Does

H.R.27, the HALT Fentanyl Act, proposes permanent scheduleI treatment for a structurally defined class of fentanyl-related substances, related trafficking-penalty amendments, and changes to controlled-substance research registration. H.R.27 itself remains pending after its February10,2025 Senate Judiciary referral. However, S.331 became Public Law119-26 on July16,2025 and enacted substantially the same substantive framework. Current21USC812,822,823 and841 already contain the principal provisions. This analysis describes the House proposal without counting those existing controls or research permissions as new present-day effects of H.R.27.

The class definition uses five specified structural modifications to fentanyl, rather than requiring each covered substance to appear on a separately published DEA list. It excludes substances controlled through the Attorney General's separate scheduling action or expressly listed in another schedule. It does not move medically used fentanyl itself from its existing schedule merely because its name appears in the bill.

Who Benefits and How

In the proposed framework, qualifying researchers and research institutions receive streamlined registration paths. Researchers already holding scheduleI orII research registrations may begin qualifying scheduleI research30days after submitting the required notice. Applicants without such registration receive registration or an order to show cause within45days of a complete notice; silence is not stated to grant them automatic registration. Qualifying research must involve an investigational-use exemption or be conducted or funded, wholly or partly, by HHS, Defense or Veterans Affairs. State authorization and declared substance/quantity information remain required.

Institutional staff may work under another researcher's registration with notice, authorization and accountability, unless the Attorney General objects within30days. Related sites under the same institutional control within one city or county may share a registration after site notification. Existing researchers may avoid a new inspection when adding a substance in the same or a higher-numbered schedule, although necessary diversion-control inspections remain allowed. These research advantages are already substantially available under the enacted law; the pending House bill does not establish a second new access benefit. No research appropriation or guaranteed scientific result is provided.

Who Bears the Burden and How

Under the framework, people engaged in unauthorized manufacture, distribution or covered import/export conduct face controlled-substance restrictions and the applicable criminal penalties. Section6 adds the defined class to the existing analogue penalty clauses: the ordinary quantity tiers concern 10grams or100grams of a mixture or substance containing a detectable amount of the covered class, with baseline five- or ten-year minimum terms respectively, subject to applicable sentencing rules and enhancements. This is not a ten-year minimum for every possession offense, and those class references are already in current law. The bill does not demonstrate that scheduling by itself reduces overdoses.

Researchers must retain notices, quantity limits, State authority and diversion safeguards. The registered researcher accepts attribution of an institutional colleague's controlled-substance acts for registration suspension or revocation proceedings, not automatic criminal liability for every act of another person. Ongoing research on a newly scheduleI substance can continue for an already scheduleI-registered researcher who applies within90days, until withdrawal or an order to show cause; a requested hearing ordinarily must occur within45days. Small-quantity research manufacturing is allowed without a manufacturing registration when properly documented, but growing marijuana is excluded and import/export requirements remain unchanged.

DEA must disclose special research application procedures, and the proposal directs six-month implementing rules with immediately effective interim rules plus comment/hearing opportunities. Its inserted DOJ Inspector General study provision uses the ambiguous anchor this Act and does not specify a congressional recipient; the enacted law instead names the HALT Act and Congress. That difference does not repeal or reset the existing report duty. Duplicated subsection insertions, completed technical corrections and relative deadlines require reconciliation if H.R.27 were later enacted; no definite additional current burden or benefit is assigned to that overlap.

Key Provisions

• Classifies the structurally defined fentanyl-related class in scheduleI, with separate-scheduling exceptions and no requirement for an exhaustive DEA substance list.
• Authorizes expedited qualifying research procedures with30day notice or45day registration/show-cause decisions, preserving State authority and quantity controls.
• Authorizes shared institutional registrations, related-site registrations and limited inspection relief while retaining diversion controls and researcher accountability.
• Authorizes continuity of qualifying ongoing research and documented small-quantity manufacturing, but excludes marijuana cultivation and preserves import/export rules.
• Requires disclosure of special research procedures, a DOJ Inspector General study and six-month implementing rules with post-interim-rule participation.
• Applies the defined class to existing trafficking penalty tiers and includes enactment applicability, technical corrections and a savings rule about prior analogue-law interpretation.